Elsevier

European Urology Focus

Volume 7, Issue 2, March 2021, Pages 440-443
European Urology Focus

Brief Correspondence – Benign Prostatic Obstruction
Clinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials

https://doi.org/10.1016/j.euf.2020.01.014Get rights and content

Abstract

We performed a post hoc analysis of data from phase 3 and 4 studies to evaluate the efficacy of silodosin 8 mg in patients with severe lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). The presence of two or more of the following criteria was adopted to define severity: total International Prostate Symptom Score (IPSS) 20–35, quality of life (QoL) score 5–6, maximum urinary flow <5 ml/s or postvoid residual volume ≥100 ml, and prostate volume ≥50 ml. Mean improvements in total (8.1 vs 4.7), storage (3.1 vs 2.0), voiding (5.0 vs 2.7), and QoL (1.3 vs 0.7) IPSS scores were significantly greater for patients receiving silodosin compared to placebo (all p <  0.0001). Mean improvements in total, storage, voiding, and QoL IPSS scores were similar for the severe and not severe LUTS cohorts. In conclusion, silodosin significantly improves symptoms and QoL in all LUTS/BPO patients, including those with severe symptoms.

Patient summary

Silodosin improves symptoms and quality of life for patients with severe lower urinary tract symptoms related to benign prostatic obstruction.

References (10)

There are more references available in the full text version of this article.
View full text